Abstract：Objective: To analyze the changes of serum interleukin-6 (IL-6), interleukin-17 (IL-17) and interleukin-35 (IL-35) levels in children with acute lymphoblastic leukemia (ALL) with different disease conditions and chemotherapy efficacy.Methods: A total of 95 children with ALL admitted to the hospital from October 2018 to October 2023 were divided into initial stage group (n=45) and advanced stage group (n=50) according to the severity of admission examination. By means of efficacy after 1 cycle of chemotherapy, they were classified into remission group (n=70) and non-remission group (n=25). Serum IL-6, IL-17 and IL-35 levels were measured among the study subjects. Binary Logistic regression analysis was used to construct an evaluation model with serum IL-6, IL-17 and IL-35 levels as variables. Receiver operating characteristic curve (ROC) was applied to analyze the evaluated value of serum IL-6, IL-17 and IL-35 on disease condition of children.Results: The levels of serum IL-6, IL-17 and IL-35 of advanced stage group were higher than initial stage group (P<0.05). Serum IL-6, IL-17 and IL-35 of non-remission group were higher than remission group (P<0.05). Logistic regression analysis indicated that serum IL-6, IL-17 and IL-35 were independent risk factors for disease progression of children with ALL, and the evaluation model was logit(P)=-7.052+0.206×IL-6+0.238×IL-17+0.406×IL-35. ROC analysis suggested the AUC of serum IL-6, IL-17 and IL-35 levels combined to evaluate the severity of childhood acute lymphoblastic leukemia was 0.918, the sensitivity was 80.00%, and the specificity was 95.56%, which was better than that of each index alone (P<0.05).Conclusion: Serum levels of IL-6, IL-17 and IL-35 are significantly different among ALL children with different disease conditions and chemotherapy efficacy. Early detection of serum IL-6, IL-17 and IL-35 can provide certain reference value for the evaluation of leukemia.
[1] Duffield AS,Mullighan CG,Borowitz MJ.International consensus classification of acute lymphoblastic leukemia/lymphoma[J].Virchows Arch,2023,482(1):11-26. [2] Brown PA,Ji L,Xu X,et al.Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children,adolescents,and young adults with first relapse of B-cell acute lymphoblastic leukemia:a randomized clinical trial[J].JAMA,2021,325(9):833-842. [3] 曾雪娇,谢仁古丽·阿力木,张瑞,等.慢性淋巴细胞白血病患者血清IFN-γ、IL-17与IL-6水平变化及其相关性分析[J].山东医药,2023,63(14):86-88. [4] 杨培仙,王盼,方磊,等.初诊急性髓系白血病患者外周血中Tregs和IL-35表达的研究[J].中国实验血液学杂志,2022,30(6):1688-1692. [5] 中华医学会儿科学分会血液学组,《中华儿科杂志》编辑委员会.儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J].中华儿科杂志,2014,52(9):641-644. [6] 沈悌,赵永强.血液病诊断及疗效标准[M].第4版.北京:科学出版社,2018.91-95. [7] Bardelli V,Arniani S,Pierini V,et al.T-cell acute lymphoblastic leukemia:biomarkers and their clinical usefulness[J].Genes (Basel),2021,12(8):1118-1137. [8] Liu RT,Wang XX,Sun JR,et al.Correlations of IL-6 and IL-10 gene polymorphisms with childhood acute lymphoblastic leukemia[J].Eur Rev Med Pharmacol Sci,2020,24(15):8048-8056. [9] Bankir M,Acik DY.IL-17 and IL-23 levels in patients with early-stage chronic lymphocytic leukemia[J].North Clin Istanb,2020,8(1):24-30. [10] 郑海莉,汤静,李明.急性淋巴细胞白血病患儿血清颗粒蛋白前体、白介素-35、骨桥蛋白变化及临床意义[J].中国小儿血液与肿瘤杂志,2022,27(3):188-192. [11] 任峰,姜俊秋.不同类型急性白血病患者血清IFN-γ、TGF-β、IL-6和IL-17水平变化及其预后判定分析[J].中国实验诊断学,2020,24(5):796-799. [12] Lu J,Dong Q,Zhang S,et al.Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling[J].Cancer Sci,2023,114(8):3287-3300. [13] Solati H,Zareinejad M,Ghavami A,et al.IL-35 and IL-18 serum levels in children with acute lymphoblastic leukemia:the relationship with prognostic factors[J].Pediatr Hematol Oncol,2020,42(4):281-286.
2024, Vol. 30 
冀公网安备13080202000677号